Abstract
IVIG is being used off-label in newborns for sepsis prophylaxis, treatment of neonatal alloimmune diseases such as HDN & NAIT.Though earlier studies supported IVIG prophylaxis in neonatal sepsis prevention, latest INIS Trial showed that IVIG is not recommended to prevent neonatal sepsis. Use in treatment of sepsis remains controversial. Cochrane systematic review suggested a beneficial effect on mortality. Significant reduction in mortality occurred with addition of IgM-enriched IVIG. Nowadays IVIG is being increasingly used in Hemolytic Disorders mainly blood group incompatibility. It has been found to reduce multiple exchange transfusions, length of hospital stay & duration of phototherapy. Possible side effects include fever, allergic reactions, hypoglycaemia, hypotension, haemolysis, fluid overload & anaphylaxis. Pending FDA approval, prompt & judicious administration of IVIG with close monitoring for any adverse events is mandatory.
Highlights
IVIG is concentrated, purified solution ofimmunoglobulins derived from pooled donor plasma
IVIG has been used in parvovirus B19 infection, hemochromatosis & neonatal Kawasaki disease
Available online at:www.pediatricreview.in 63 | P a g e no effect of IVIG in neonatal sepsis prevention
Summary
IVIG is concentrated, purified solution ofimmunoglobulins derived from pooled donor plasma. It is being used off-label in newborns for sepsis prophylaxis in LBW infants & treatment of neonatal alloimmune diseases such as HDN&NAIT. Howeverin a systematic review of 19 trials involving >5000 preterm / LBW infants, prophylactic IVIG reduced the rate of late-onset infection by 3% with no significant reduction in mortality [15].Other studies found [16,17,18,19] found
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
